New Chief Medical Officer for Valneva

Valneva, a specialty vaccine company based in France, has appointed Juan Carlos Jaramillo, as Chief Medical Officer and member of the Management Board.

Starting 1st October, Juan Carlos will succeed Wolfgang Bender, who will retire after a hand-over period, at the end of October.

Dr Juan Carlos Jaramillo has worked in various pharmaceutical/biotech organizations, including GlaxoSmithKline, Grünenthal and Daiichi Sankyo.

“I am delighted to be joining Valneva at an extremely exciting time. Valneva has a great and valuable portfolio of vaccines in development including chikungunya, Lyme and SARS-COV-2,” he said.

CEO Thomas Lingelbach added: “We are thrilled that Juan Carlos is joining Valneva. His expertise and multi-cultural leadership skills will be a great addition to the company. We sincerely thank Wolfgang for his outstanding leadership and his great contributions to the Company and its strategic development over the past four years.

“He has played a pivotal role in advancing the Company´s lead vaccine R&D programs against Lyme disease and Chikungunya and in building an excellent team. Everyone at Valneva wishes him very well in his retirement.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news